Drawing for PEMPHAGE

USPTO serial 79088959

PEMPHAGE

Reviewed by CopyMark Law Group

Reg. 4095056Status 404
Filing date
Status date
Registration date
Feb 7, 2012
Examiner
BROWN, TINA
Law office

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with PEMPHAGE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Scott D. Woldow

Scott D. Woldow SMITH, GAMBRELL & RUSSELL, LLP1055 Thomas Jefferson St., NWSuite 400WASHINGTON, DC 20007

Goods and services

ClassDescriptionStatusFirst use
001[ Chemicals used in industry and science ]SECTION 71 - CANCELLED
005[ Pharmaceutical anti-allergic preparations and substances, Pharmaceutical for the treatment of erectile dysfunction, Pharmaceutical preparations, namely, anticoagulants, Pharmaceutical preparations, namely, antidepressants, Pharmaceutical preparations, namely, appetite suppressants, Pharmaceutical preparations for use in chemotherapy, Pharmaceutical preparation for the treatment of gout, Pharmaceutical preparations for the treatment of heart rhythm disorders, Pharmaceutical preparations for the treatment of stem cell mobilization, Pharmaceutical preparations for the treatment of infectious diseases, Pharmaceutical preparations acting on the central nervous system, Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases, Pharmaceutical preparations for animal skincare, Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension, Pharmaceutical preparations for ocular or intraocular surgery, Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis, Pharmaceutical preparations for treating allergic rhinitis and asthma, Pharmaceutical preparations for treating diabetes, Pharmaceutical preparations for treating skin disorders, Pharmaceutical preparations for use in dermatology, Pharmaceutical preparations for wounds, Pharmaceutical preparations for use in urology, Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in humans, Pharmaceutical products and preparations against dry skin caused by pregnancy, Pharmaceutical products and preparations for chloasma, Pharmaceutical products and preparations for hydrating the skin during pregnancy, Pharmaceutical products and preparations for pregnancy blemishes, Pharmaceutical products and preparations for preventing skin blemishes during pregnancy, Pharmaceutical products and preparations to prevent stretch marks, Pharmaceutical products and preparations to prevent swelling in the legs, Pharmaceutical products for ophthalmological use, Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer, Pharmaceutical products for treating respiratory diseases and asthma, Pharmaceutical skin lotions, Pharmaceutical solutions used in dialysis, Pharmaceuticals, namely, antihelmintics, Pharmaceuticals, namely, inducers of erections, Pharmaceuticals, namely, lipid lowering agents, Pharmaceuticals, namely, psychotropics, Pharmaceuticals, namely, anti-infectives; and sanitary preparations for medical purposes; dietetic foods adapted for medical use, medical plasters, dressings for wounds, burns and surgery; dental impression materials; disinfectants for hygienic purposes ]SECTION 71 - CANCELLED
042Scientific and technological services in the nature of scientific research in the fields of pharmaceuticals and bio-chemistry; design of new products for others in the fields of pharmaceuticals and bio-chemistry; industrial analysis, namely, quality evaluation and analysis, quality assurance, and quality control and research services in the fields of pharmaceuticals and bio-chemistry; industrial analysis, namely, industrial design in the fields of pharmaceuticals and bio-chemistrySECTION 70 - CANCELLED

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 7, 2021DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Nov 7, 2021DETHDEATH OF INTERNATIONAL REGISTRATION
Feb 7, 2021REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Jul 26, 2019INNPPARTIAL INVALIDATION PROCESSED BY THE IB
May 18, 2019INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
May 18, 2019INPCINVALIDATION PROCESSED
Apr 27, 2019INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Aug 27, 2018NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Aug 27, 201871.PREGISTERED - PARTIAL SEC 71 ACCEPTED
Aug 23, 2018APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL
Aug 7, 2018ES71TEAS SECTION 71 RECEIVED
Jul 19, 2018NREPNEW REPRESENTATIVE AT IB RECEIVED
Feb 7, 2017REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
May 30, 2013TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED
May 14, 2013FINOFINAL DECISION TRANSACTION PROCESSED BY IB
Jul 6, 2012FICSFINAL DISPOSITION NOTICE SENT TO IB
Jul 6, 2012FIMPFINAL DISPOSITION PROCESSED
Jun 30, 2012GPNXNOTIFICATION PROCESSED BY IB
May 7, 2012FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 7, 2012R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 22, 2011NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 22, 2011PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 3, 2011OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 2, 2011OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 2, 2011NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 20, 2011PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 14, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Oct 14, 2011TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Oct 14, 2011CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 5, 2011ALIEASSIGNED TO LIE
Sep 28, 2011ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 20, 2011GNFNNOTIFICATION OF FINAL REFUSAL EMAILED
Jul 20, 2011GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 20, 2011CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 17, 2011TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Jun 17, 2011CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 17, 2011TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 29, 2011RFNTREFUSAL PROCESSED BY IB
Jan 12, 2011RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 12, 2011RFRRREFUSAL PROCESSED BY MPU
Jan 12, 2011RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 11, 2011CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 5, 2011DOCKASSIGNED TO EXAMINER
Nov 23, 2010MAFRAPPLICATION FILING RECEIPT MAILED
Nov 19, 2010NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 18, 2010REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance